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ABSTRACT 
Haloperidol is a classic antipsychotic drug known for its propensity to cause extrapyramidal 
symptoms and impaired memory, owing to blockade of striatal dopamine D2 receptors. Cin-
narizine is a calcium channel blocker with D2 receptor blocking properties which is widely 
used in treatment of vertiginous disorders. The present study aimed to see whether cinnarizine 
would worsen the effect of haloperidol on memory function and on oxidative stress in mice 
brain. Cinnarizine (5, 10 or 20 mg/kg), haloperidol, or haloperidol combined with cinnarizine 
was administered daily via the subcutaneous route and mice were examined on weekly basis 
for their ability to locate a submerged plate in the water maze test. Mice were euthanized 30 
days after starting drug injection. Malondialdehyde (MDA), reduced glutathione (GSH) and 
nitric oxide (nitrite/nitrate) were determined in brain. Haloperidol substantially impaired wa-
ter maze performance. The mean time taken to find the escape platform (latency) was signifi-
cantly delayed by haloperidol (2 mg/kg, i.p.) on weeks 1-8 of the test, compared with saline 
control group. In contrast, those treated with haloperidol and cinnarizine showed significantly 
shorter latencies, which indicated that learning had occurred immediately. Haloperidol result-
ed in increased MDA in cortex, striatum, cerebellum and midbrain. GSH decreased in cortex, 
striatum and cerebellum and nitric oxide increased in cortex. Meanwhile, treatment with cin-
narizine (20 mg/kg) and haloperidol resulted in significant decrease in MDA cortex, striatum, 
cerebellum and midbrain and an increase in GSH in cortex and striatum, compared with 
haloperidol group. These data suggest that cinnarizine improves the haloperidol induced brain 
oxidative stress and impairment of learning and memory in the water maze test in mice. 
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INTRODUCTION 
Memory or the acquisition and recall of 
past experiences and learned information is 
fundamental to human life. Memory disor-
ders can occur as a part of normal aging 
(mild cognitive impairment), in neuro-
degenerative diseases e.g., Alzheimer’s dis-
ease and Parkinson’s disease (Sawamoto et 
al., 2008) or psychiatric disorders e.g., ma-
jor depressive illness and schizophrenia. 
Memory impairment can also be due to 
medications. In this context, antipsychotic 
drugs, used in the treatment of schizophre-
nia, have been associated with worsening of 
memory tasks; this being more evident with 
the typical antipsychotics such as haloperi-
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dol in contrast to atypical or newer genera-
tion antipsychotics which are thought to act 
via both D2 receptor antagonism and 
5HT2A receptor antagonism (Beuzen et al., 
1999; Gemperle et al., 2003; Houthoofd et 
al., 2008). 
Haloperidol, a classic antipsychotic 
drug, is widely used to treat schizophrenic 
symptoms, to control agitation in patients 
with acute illness and delirium and also to 
control delusions, hallucinations, agitation, 
and other disruptive behavioral symptoms 
associated with Alzheimer’s disease. The 
drug exerts its effect by blocking dopamine 
D2 receptors in the prefrontal cortex. 
Meanwhile, blocking striatal D2 receptors 
accounts for the liability of the drug to 
cause extrapyramidal side effects. Haloperi-
dol impairs learning and memory perfor-
mance in humans as well as in experimental 
animals. Thus, haloperidol impaired spatial 
working memory performance and planning 
ability in healthy volunteers (Legangneux et 
al., 2000; Lustig and Meck, 2005) and 
worsened recent autobiographical memory 
scores of patients with Alzheimer’s disease 
(Harrison and Therrien, 2007). In experi-
mental animals, haloperidol impaired 
memory retention in water-maze task and in 
step-through test (Terry et al., 2003; Hou et 
al., 2006; Abdel-Salam and Nada, 2011).  
Cinnarizine (1-diphenylmethyl-4-(3-
phenyl-2-propenyl) piperazine) is a calcium 
channel blocker and a vasodilator used in 
treatment of vertiginous disorders, cerebro-
vascular disturbances and in migraine 
prophylaxis (Pianese et al., 2002; Man-
sooreh et al., 2006; Desloovere, 2008). 
Cinnarizine has been reported to cause ex-
trapyramidal side effects in humans (Teive 
et al., 2004; Hirose, 2006), primates (Gar-
cia-Ruiz et al., 1992) and rodents 
(Dall’Igna et al., 2005). The inhibition of 
calcium influx into striatal cells and direct 
dopamine D1 and D2 receptor blocking 
properties (Reiriz et al., 1994; Brücke et al., 
1995; Daniel and Mauro, 1995), inhibition 
of mitochondrial complexes I and II (Veitch 
and Hue, 1994) and inhibition of proton 
pumping and catecholamine uptake in stor-
age vesicles (Terland and Flatmark, 1999) 
might contribute to the drug-induced par-
kinsonism. Cinnarizine might also impair 
memory performance in healthy volunteers 
(Golding et al., 1989; Parrott et al., 1990). 
Oxidative stress defined as a breach in 
the balance between free radical production 
and antioxidant defense mechanisms has 
been implicated in the pathogenesis of neu-
rodegenerative disorders (Mattson, 2002), 
depression (Sarandol et al., 2007) and 
schizophrenia (Behrens and Sejnowski, 
2009; Bošković et al., 2011). Oxidative 
stress also plays an important role in the 
decline in cognitive functions associated 
with aging or caused by different patholog-
ical states such as Alzheimer’s disease or 
Parkinson’s disease. Oxidative stress and 
inflammatory responses underly neuronal 
injury and memory impairment caused by 
A deposition in animal models of Alz-
heimer’s disease, which could be prevented 
by antioxidants (Um et al., 2009; Lu et al., 
2009; Dumont et al., 2009). Oxidative 
stress has also been associated with age re-
lated deficits in learning and memory and in 
cognitive impairment caused by glucocorti-
coids (Sato et al., 2010) or that caused by 
nicotine (Hritcu et al., 2011). There is also 
an evidence to suggest increased oxidative 
stress by antipsychotic drugs and in particu-
lar the typical or first generation antipsy-
chotic drugs compared with the newer atyp-
ical antipsychotics (Dakhale et al., 2004; 
Pillai et al., 2007; Martins et al., 2008).  
Therefore the present study aimed to: 
(1) investigate the effect of the classic neu-
roleptic drug haloperidol and the calcium 
channel and dopamine D2 blocking drug 
cinnarizine in the working memory version 
of MWM test and on brain oxidative stress 
(2) test whether treatment with cinnarizine 
would worsen the effect of haloperidol on 
memory function and oxidative stress in 
mice brain. 
 
MATERIALS AND METHODS 
Animals 
Swiss male albino mice 20-22 g of body 
weight (age: 5-6 weeks) were used. Mice 
were obtained from animal house colony of 
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the National Research Centre (Cairo, 
Egypt). Mice were housed under standard 
laboratory conditions with 1 h of light-dark 
cycle and temperature between 24 °C and 
25 °C. Standard laboratory food and water 
were provided ad libitum. Animal proce-
dures were performed in accordance with 
the Ethics Committee of the National Re-
search Centre and followed the recommen-
dations of the National Institutes of Health 
Guide for Care and Use of Laboratory An-
imals (Publication No. 85-23, Revised 
1985). Equal groups of 6 mice each were 
used in all experiments.  
 
Cognitive testing 
The maze consisted of a glass tank, nar-
rowed to 20 cm wide, 40 cm in height, 
70 cm in length, filled to a depth of 21 cm 
with water maintained at 25 °C. The escape 
glass platform was hidden from sight, sub-
merged 1 cm below the surface of the water 
at the end of the tank (Dunnett et al., 2003). 
Haloperidol (1 mg/kg), cinnarizine (5, 10 or 
20 mg/kg), haloperidol (1 mg/kg) + cinna-
rizine (5, 10 or 20 mg/kg) or saline was 
administered daily via the subcutaneous 
route and mice were examined on weekly 
basis for their ability to locate a submerged 
plate. Drugs were given 30 min before test-
ing. Once the mice reached the platform, it 
remained there for 15 sec (trial 1; reference 
memory or acquisition trial). At the end of 
each trial, the mice were towel dried, re-
turned to their home cage (where a heat 
lamp was available), and 3 min elapsed be-
fore the next trial (trials 2 and 3; working 
memory or retrieval trial), which used the 
same platform location and start position as 
trial 1. The latency to find the platform 
(sec) is assessed with a stopwatch.  
 
Biochemical analysis 
Mice were euthanized 30 days after 
starting drug injection by decapitation un-
der ether anaesthesia, brains and livers were 
excised, washed with ice-cold saline solu-
tion (0.9 % NaCl), weighed and stored 
at -80 °C for the biochemical analyses. The 
liver was homogenized with 0.1 M phos-
phate buffer saline at pH 7.4, to give a final 
concentration of 10 % w/v for the biochem-
ical assays.  
 
Determinaion of lipid peroxidation 
Lipid peroxidation was assayed by 
measuring the level of malondialdehyde 
(MDA) in the brain tissues. Malondialde-
hyde was determined by measuring thio-
barbituric reactive species using the method 
of Ruiz-Larrea et al. (1994), in which the 
thiobarbituric acid reactive substances react 
with thiobarbituric acid to produce a red 
colored complex having peak absorbance at 
532 nm. 
 
Determination of reduced glutathione  
Reduced glutathione (GSH) was deter-
mined by Ellman's method (1959). The pro-
cedure is based on the reduction of 
Ellman´s reagent by –SH groups of GSH to 
form 2-nitro-s-mercaptobenzoic acid, the 
nitromercaptobenzoic acid anion has an in-
tense yellow color which can be determined 
spectrophotometrically. 
 
Determination of nitric oxide  
Nitric oxide measured as nitrite was de-
termined by using Griess reagent, according 
to the method of Moshage et al. (1995) 
where nitrite, stable end product of nitric 
oxide radical, is mostly used as indicator 
for the production of nitric oxide. 
 
Drugs  
Haloperidol (Kahira Pharm and Chem. 
IND, Cairo, ARE), cinnarizine (Arab Drug 
Co., Cairo, A.R.E). All drugs were dis-
solved in isotonic (0.9 % NaCl) saline solu-
tion immediately before use. The doses of 
drugs used in the study were based on pre-
vious studies (Invernizzi et al., 2003; Ab-
del-Salam, 2007).  
 
Statistical analysis 
Data are expressed as mean ± SEM. The 
data were analyzed by one way ANOVA 
and by repeated measures (session x treat-
ment) ANOVA, followed by Duncan’s 
multiple range test, using SPSS software 
(SAS Institute Inc., Cary, NC). A probabil-
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ity value of less than 0.05 was considered 
statistically significant.  
 
RESULTS 
As shown in Figures 1 and 2, treatment 
with haloperidol substantially impaired wa-
ter maze performance. The mean time taken 
to find the escape platform (latency) was 
significantly delayed by haloperidol 
(1 mg/kg) on weeks 1-8 compared with sa-
line-treated control group. Cinnarizine ad-
ministered at doses of 5, 10 or 20 mg/kg did 
not alter escape latency. Moreover, the ad-
ministration of cinnarizine with haloperidol 
did not worsen escape latencies. On the 
contrary, mice treated with haloperidol and 
cinnarizine showed significantly shorter 
latencies, compared with the haloperidol 
only-treated group, which suggested that 
memory was improved by the drug treat-
ment (Figures 1, 2).  
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Figure 1: Effect of cinnarizine, haloperidol or 
cinnarizine combined with haloperidol on the 
latency to find hidden platform in the MWM test. 
Drugs were administered daily via subcutane-
ous route for one month and observations were 
done on weekly basis. Asterisks indicate signifi-
cant change from the saline control group. 
 
The mean time to reach the platform 
over 8 weeks for the saline (group 1), cin-
narizine (5, 10 or 20 mg/kg) (groups 2-4), 
haloperidol only (group 5), haloperidol + 
cinnarizine (5, 10 or 20 mg/kg) (groups 6-
8) was 1.54 ± 0.05, 1.46 ± 0.04, 1.31 ± 
0.03, 1.29 ± 0.03, 4.13 ± 0.38, 4.14 ± 0.44, 
3.33 ± 0.24, 3.12 ± 0.24, respectively. 
There was a significant main drug effect (F 
= 20.3, p = 0.0001), a significant main ef-
fect of weeks (F = 2.99, p = 0.0001), but no 
significant drug x weeks interaction or trial 
x weeks interaction. All groups showed 
progressively shorter time to locate the hid-
den plate improved over 8 weeks. The 
groups treated with haloperidol alone or 
haloperidol + cinnarizine 5 mg/kg showed 
significantly longer time to locate the hid-
den platform compared with all other 
groups. 
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Figure 2: The average mean latency ± SEM to 
locate a submerged plate in the MWM test over 
four weeks. Mice received daily injections of 
saline, cinnarizine, haloperidol or cinnarizine + 
haloperidol and were tested weekly. Asterisks 
indicate significant change from the saline con-
trol group and between different groups as indi-
cated in the figure.  
 
A repeated measure ANOVA was done 
to compare latency to find the hidden plate 
in the first, second, and third trial across 
8 weeks. In the first trial, the mean time to 
reach the platform over 8 weeks for the sa-
line (group 1), cinnarizine (5, 10 or 
20 mg/kg) (groups 2-4), haloperidol only 
(group 5), haloperidol + cinnarizine (5, 10 
or 20 mg/kg) (groups 6-8) was 1.52 ± 0.08, 
1.37 ± 0.06, 1.45 ± 0.07, 1.53 ± 0.16, 4.76 ± 
0.51, 4.78 ± 0.32, 3.86 ± 0.26, 3.18 ± 0.33, 
respectively. On the first trial there was a 
significant main effect of drug (F = 13.51, 
p= 0.0001), a significant main effect of 
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weeks (F = 5.96, p= 0.0001) but no signifi-
cant drug x weeks interaction. Comparing 
different groups in trial 1 indicated that cin-
narizine at 10 or 20 mg/kg with haloperidol 
significantly decreased escape latency when 
compared with the haloperidol only treated 
group. This suggested that the impairment 
in memory retention observed in the 
haloperidol-treated vs. saline group was 
improved by the high dose of cinnarizine. 
The mean time to reach the platform on the 
acquisition trials was also decreased by 
cinnarizine at 10 or 20 mg/kg when com-
pared with the haloperidol only group (Fig-
ure 3A).  
In the second trial the mean time to 
reach the platform over 8 weeks for the sa-
line (group 1), cinnarizine (5, 10 or 
20 mg/kg) (groups 2-4), haloperidol only 
(group 5), haloperidol + cinnarizine (5, 10 
or 20 mg/kg) (groups 6-8) was 1.46 ± 0.06, 
1.54 ± 0.22, 1.24 ± 0.03, 1.17 ± 0.03, 3.57 ± 
0.32, 3.78 ± 0.28, 2.95 ± 0.23, 2.92 ± 0.24, 
respectively. There was a significant main 
effect of drug (F = 24.6, p= 0.0001) and a 
significant main effect of weeks (F = 11.16, 
p= 0.001) (Figure 3B).  
In the third trial the mean time to reach 
the platform over 8 weeks for the saline 
(group 1), cinnarizine (5, 10 or 20 mg/kg) 
(groups 2-4), haloperidol only (group 5), 
haloperidol + cinnarizine (5, 10 or 20 
mg/kg) (groups 6-8) was 1.64 ± 0.11, 1.8 ± 
0.02, 1.18 ± 0.03, 1.32 ± 0.02, 4.06 ± 0.38, 
3.85 ± 0.37, 3.19 ± 0.29, 3.28 ± 0.26, re-
spectively. There was a significant main 
effect of drug (F = 15.0, p= .0001), a signif-
icant main effect of weeks (F = 10.25, p= 
.0001) and a significant drug x weeks inter-
action (F = 1.57, p = 0.01) (Figure 3C).  
 
Figure 3 (A-C): The average mean latency ± 
SEM of first (A); second (B) and third (C) trial to 
locate a submerged plate in the MWM test over 
four weeks. Mice received daily injections of 
saline, cinnarizine, haloperidol or cinnarizine + 
haloperidol and were tested weekly. Asterisks 
indicate significant change from the saline con-
trol group and between different groups as indi-
cated in the figure.  
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Lipid peroxidation 
In haloperidol only treated mice, there 
was a significant increase in lipid peroxida-
tion in the cortex by 87.5 % (46.7  3.4 vs 
24.9  1.3 nmol/g, p<0.05), striatum by 
47.3 % (44.5  2.3 vs 30.2  1.5, nmol/g, 
p<0.05), cerebellum by 24.0 % (41.3  2.1 
vs 33.3  1.4 nmol/g, p<0.05) and midbrain 
by 13.0 % (41.3  2.1 vs 33.3  1.4 nmol/g, 
p<0.05), compared with the saline-treated 
group. Cinnarizine alone did not alter MDA 
in cortex, striatum or cerebellum. Cinnariz-
ine at 20 mg/kg decreased MDA in mid-
brain by 19.6 % (p<0.05) compared with 
the saline group (Figures 4A-B). Mice 
treated with haloperidol and cinnarizine at 
10 mg/kg showed decreased MDA in cortex 
and striatum by 17.3 % (p<0.05) and 
20.0 % (p<0.05), respectively, compared 
with haloperidol control value. With cinna-
rizine being given at 20 mg/kg with 
haloperidol, there was 30.8, 25.4, 24.2 and 
19.2 % decrease in MDA in cortex (32.3  
1.4 vs 46.7  3.4 nmol/g, p<0.05), striatum 
(33.2  1.6 vs 44.5  2.3 nmol/g, p<0.05), 
cerebellum (31.3  1.7 vs 41.3  2.1 
nmol/g, p<0.05) and midbrain (30.8  1.2 
vs 38.1  1.4 nmol/g, p<0.05), compared to 
haloperidol only control value (Figures 4A-
B).  
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Figure 4A, B: Malondialdehyde (MDA) in cor-
tex and striatum (A) and in cerebellum and 
midbrain (B) in mice treated with cinnarizine, 
haloperidol or cinnarizine + haloperidol for one 
month. *: P< 0.05 vs corresponding saline con-
trol value. + : P< 0.05 vs. haloperidol only-
treated group 
 
Reduced glutathione 
The administration of haloperidol re-
sulted in a significant decrease of reduced 
glutathione (GSH) (p<0.05) by 25.6 %, 
30.6 % and 25.7 % in the cortex (7.4  0.31 
vs 9.95  0.20 µmol/g, p<0.05), striatum 
(6.8  0.22 vs 9.8  0.54 µmol/g, p<0.05) 
and cerebellum (7.5  0.22 vs 10.1  
0.41 µmol/g, p<0.05), respectively com-
pared with the saline-treated group. A non-
significant decrease in GSH by 11.6 % was 
registered in the midbrain (9.9  0.66 vs 
11.2  0.70 µg/g, p>0.05). No-significant 
effect on GSH was observed in cinnarizine 
only-treated mice. However, mice treated 
with cinnarizine (5, 10 or 20 mg/kg) and 
haloperidol showed significant increase by 
14.9 %, 16.2 % and 23 % in GSH in the 
cortex as compared to haloperidol only-
treated group (8.5  0.10, 8.6  0.18 and 9.1 
 0.21 vs 7.4  0.31 µmol/g, p<0.05). Mice 
treated with cinnarizine 20 mg/kg and 
haloperidol showed significant increase by 
18.2 % in the striatum compared to 
haloperidol only-treated group (8.04  0.34 
vs 6.8  0.22 µmol/g, p<0.05). Moreover, 
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mice treated with cinnarizine 20 mg/kg and 
haloperidol showed significant increase by 
18.7 % in the cerebellum compared to 
haloperidol only-treated group (8.9  0.31 
vs 7.5  0.22 µmol/g, p<0.05). A non-
significant increase in GSH by 12.6 % was 
observed in the midbrain in mice treated 
with cinnarizine 20 mg/kg and haloperidol 
compared with the haloperidol only treat-
ment group (p>0.05) (Figures 5A-B). 
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Figures 5A, B: Reduced glutathione (GSH) in 
cortex and striatum (A) and in cerebellum and 
midbrain (B) in mice treated with cinnarizine, 
haloperidol or cinnarizine + haloperidol for one 
month. *: P< 0.05 vs corresponding saline con-
trol value. +: P< 0.05 vs. haloperidol only-
treated group 
 
Nitric oxide 
The level of nitric oxide in the cortex 
was reduced by 30.5 % after haloperidol 
treatment, compared with the saline-treated 
group (39.8  2.1 vs 30.5  2.6 µmol/g, 
p<0.05). Cinnarizine alone did not alter ni-
tric oxide. In addition, no significant 
changes in the level of nitric oxide were 
observed in cinnarizine + haloperidol com-
pared with the haloperidol only treatment 
group (Figure 6). 
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Figure 6: Nitric oxide in brain (cortex) of mice 
treated with cinnarizine, haloperidol or cinnariz-
ine + haloperidol for one month. *: P< 0.05 vs 
corresponding saline control value 
 
DISCUSSION 
The present study examined the effect 
of the typical antipsychotic drug haloperi-
dol and the calcium channel blocking agent 
cinnarizine on working memory and brain 
oxidative stress in mice. Both drugs are 
well known for their propensity to cause 
extrapyramidal symptoms in humans and in 
experimental animals, although for cinna-
rizine, high doses and old age are important 
predisposing factors (Thanvi and Tread-
well, 2009). In light of the above, it seemed 
likely that greater inhibition of the dopa-
mine D2 receptors by the combined treat-
ment with both cinnarizine and haloperidol 
would result in profound memory impair-
ment as well as markedly increased oxida-
tive stress. The administration of haloperi-
dol to mice impaired learning and memory. 
Both the acquisition and retention of infor-
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mation were impaired by the drug. Mice 
spent more time to locate the submerged 
platform compared with their normal coun-
terparts, which is in accordance with other 
published results (Abdel-Salam and Nada, 
2011). Meanwhile, the administration of 
cinnarizine, improved the memory impair-
ment observed in haloperidol-treated mice. 
In the present study, the dose of haloperidol 
used was shown to impair locomotor activi-
ty in other studies (Invernizzi et al., 2003) 
and a drug influence on motor activity thus 
cannot be ruled out. The water maze test, 
however, is primarily a test of cognition 
(spatial learning/memory) (Hamm et al., 
1992) and the negative effects of haloperi-
dol in the water maze task are likely to be 
memory-related (Terry et al., 2003). Studies 
indicated impairment of learning and 
memory by haloperidol. Haloperidol and 
several atypical neuroleptics e.g., clozapine, 
olanzapine, and risperidone impaired place 
navigation in the MWM when administered 
30 min before testing (Skarsfeldt, 1996). 
Haloperidol caused impairment in memory 
retention observed by increased latency 
time to find the original location of plat-
form in water-maze task (Barcelos et al., 
2010). Haloperidol as well as the atypical 
antipsychotic clozapine impaired acquisi-
tion process and consolidation process, re-
spectively, in step-through test. Both drugs 
impaired spatial learning function of mice 
in water maze task (Hou et al., 2006). The 
chronic administration of haloperidol sig-
nificantly impaired learning performance in 
rats when compared to both vehicle con-
trols and the atypical agents together with 
reduced choline acetyltransferase staining 
in several brain regions, including the cor-
tex, caudate-putamen, and hippocampus 
(Terry et al., 2003). Both haloperidol and 
risperidone produced diminished motor ac-
tivity and exploration, impaired working 
memory performances, and increased anx-
iety levels. These effects were more pro-
nounced in haloperidol-treated animals 
(Karl et al., 2006). In man, haloperidol sig-
nificantly attenuated error-related negativi-
ty, impaired learning of time intervals, and 
tended to cause more errors of commission, 
compared to placebo (Zirnheld et al., 2004). 
The drug also worsened the immediate free 
and delayed free and cued recall deficits 
produced by Delta-9-tetrahydrocannabinol 
(D'Souza et al., 2008). 
The dopaminergic system plays an im-
portant role in memory processes (Wisman 
et al., 2008; Costa et al., 2008; Schott et al., 
2006; Bäckman et al., 2011). In humans, 
working memory capacity correlated posi-
tively with striatal (caudate) dopaminergic 
function and predicted dopamine synthesis 
capacity in the striatum, where subjects 
with low working memory capacity have 
low dopamine synthesis capacity in the stri-
atum and vice versa (Cools et al., 2008). In 
support of this notion also is the finding 
that dopamine transmission is abnormal in 
the brains of patients with schizophrenia 
and working memory deficit is a core dys-
function in schizophrenia (Tanaka, 2006). 
In patients with Parkinson’s disease, L-
dopa administration significantly improved 
performance, restoring the prospective 
memory deficit, possibly through the re-
placement of dopamine levels in fronto-
striatal pathways (Costa et al., 2008). In 
healthy volunteers, increased release of en-
dogenous dopamine in the dorsomedial as-
pect of posterior putamen and in the anteri-
or part of the caudate bilaterally was ob-
served, during task performance (explicit 
motor memory task) (Badgaiyan et al., 
2008). Chronic blockade of dopamine D2 
receptors by antipsychotic drugs, down-
regulates D1 receptors in the prefrontal cor-
tex and produces severe impairments in 
working memory, which could be reversed 
by Dopamine D1 receptor stimulation 
(Castner et al., 2000). However, a greater 
contribution of D2- over D1-like receptors 
to both spatial working memory and object-
location associative memory seems more 
likely (Von Huben et al., 2006). Drugs with 
dopaminergic agonist activity have been 
shown to improve memory function. Thus, 
piribedil displayed beneficial effects against 
aging-related memory impairments in two 
radial-maze experiments in mice (Marighet-
to et al., 2008) and pergolide facilitated spa-
tial memory and improved brain oxidative 
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balance in experimental Parkinson's disease 
(Ciobica et al., 2012). 
Meanwhile, there are only few reports 
that have explored the effects of cinnarizine 
on working memory in man. Parrott and 
Wesnes (1987) showed that cinnarizine sig-
nificantly impaired psychomotor perfor-
mance, information processing and feelings 
of alertness. In young healthy volunteers, 
oral cinnarizine was found to be less likely 
than hyoscine to produce unwanted decre-
ments in performance (Golding et al., 
1989). Cinnarizine (and scopolamine) also 
impaired memory error and four choice re-
action time (Parrott et al., 1990). In the pre-
sent study, cinnarizine failed to affect work-
ing memory in mice and even improved 
memory impairment due to haloperidol. 
Cinnarizine exhibits a dopamine D2 recep-
tor blocking property and might therefore 
impair working memory. The drug, howev-
er, has been shown to exhibit a potential 
antipsychotic effect with an atypical profile 
(Dall'Igna et al., 2005). Cinnarizine also 
possesses other important pharmacological 
actions that could be of relevance to its ef-
fects observed in the present study. Cinna-
rizine can influence cognitive functions by 
activating sigma-1 receptors in the CNS. 
Sigma-1 agonists show powerful anti-
amnesic and neuroprotective effects in a 
large variety of animal models of cognitive 
dysfunction (Van Waarde et al., 2011). 
Cinnarizine (and its di-fluorinated deriva-
tive flunarizine) is a calcium channel an-
tagonist and has been shown to exhibit anti-
inflammatory, antidepressant (Abdel-
Salam, 2007) as well as neuroprotective 
effects (Belostotskaia et al., 2003). Cinna-
rizine (50 mg/kg, twice per day) prevented 
the hypoxic brain edema development, re-
stored NAD+ dependent oxidation of a suc-
cinate substrate, normalized emotional-
exploratory activity, and caused hyperlo-
comotion of the experimental animals, 
while not influencing a high level of activi-
ty of the blood antioxidant system (Belos-
totskaia et al., 2003). Cinnarizine (and 
flunarizine) at low concentrations (< 50 mi-
croM) inhibited the mitochondrial permea-
bility transition induced either by Ca2+ 
alone or in the presence of tert-butylhydro-
peroxide. This was accompanied by the in-
hibition of NADPH oxidation and the resto-
ration of the mitochondrial membrane po-
tential decreased by a high concentration of 
Ca2+ (25 microM) (Elimadi et al., 1998). In 
other studies, flunarizine significantly facil-
itated memory retention (Petkov et al., 
2000). Cinnarizine and flunarizine inhibited 
catecholamine uptake in storage vesicles 
(Terland and Flatmark, 1999), an effect 
which might have important implications 
on memory processing. 
In the present work, the effect of both 
haloperidol and cinnarizine on brain oxida-
tive stress in mice was studied. The admin-
istration of haloperidol resulted in increased 
MDA, nitric oxide and decreased GSH in 
several brain areas. The effect of haloperi-
dol on MDA and GSH were mitigated by 
co-treatment with cinnarizine. This finding 
together with the improvement in working 
memory by cinnarizine administration, sug-
gests that oxidative stress contributes to the 
haloperidol-induced learning and memory 
deficits in mice. Several studies indicated 
increased oxidative stress after the admin-
istration of haloperidol in rodents. Chronic 
treatment with haloperidol induced a signif-
icant decrease in the cellular glutathione 
content in selected areas of the brain (cere-
bellum, striatum and cortex) and in the liver 
(Vairetti et al., 1999). Haloperidol also in-
duced a significant decrease in ATP and 
energy charge (Vairetti et al., 1999). In 
mice, haloperidol (1 mg/kg, i.p.) adminis-
tered for 18 days, increased MDA, de-
creased GSH and increased nitric oxide in 
brain (Abdel-Salam et al., 2012). In rats, 
chronic haloperidol (2 mg/kg/day) admin-
istration increased brain lipid peroxidation 
and decreased both manganese-superoxide 
dismutase and copper-zinc superoxide dis-
mutase (Pillai et al., 2007). Increased lipid 
peroxidation in rat striatum was observed 
after treatment with haloperidol (1.5 
mg/kg/day) for 28 days (Martins et al., 
2008). Evidence suggested the involvement 
of free radicals in the development of be-
havioral hypersensitivity by haloperidol 
(Daya et al., 2011). Studies also have 
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shown increased oxidative stress in brain in 
association with the deficits in memory 
function induced by ethanol (Gönenç et al., 
2005), intracerebral -amyloid protein in-
jection (Um et al., 2009; Lu et al., 2009), 
glucocorticoids (Sato et al., 2010) as well as 
in the SAMP8 mice strain which exhibits 
memory impairment by 12 months of age 
(Farr et al., 2003). In these studies, the ad-
ministration of antioxidants e.g., -lipoic 
acid, N-acetylcysteine, silibinin or melato-
nin improved memory performance togeth-
er with alleviation of oxidative stress, 
thereby suggesting a role for the latter in 
the cognitive decline seen in these models. 
Modulation of oxidative stress might be a 
mechanism that underlies the beneficial ef-
fect of cinnarizine on the haloperidol-
induced memory impairment. 
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